Two prospective multicenter studies demonstrated that a soluble fms-like tyrosine kinase 1
(sFlt-1)/placental growth factor (PlGF) ratio cutoff of≤ 38 can rule out preeclampsia within 1 …

Preeclampsia is a relatively common pregnancy-related condition associated with serious
maternal and fetal morbidity and mortality. It is now well established that anti-angiogenic …

Background: It is difficult to evaluate whether monitoring serum sFlt-1, PlGF, or sFlt-1/PlGF in
pregnant women who are suspected of having PE can significantly shorten the PE diagnosis …

Objectives Assess the usefulness of the sFlt-1/PlGF ratio for the differential diagnosis of
uncontrolled chronic hypertension vs. superimposed preeclampsia. Study design We …

Abstract Objective: The Elecsys® immunoassay sFlt-1/PlGF ratio and the Triage® PlGF
assay were compared (in a prospective, multicenter, case-control study) for diagnosis of …

Purpose Preeclampsia is one of the leading causes of maternal and perinatal morbidity and
mortality. Till date despite years of research into the condition, predicting the onset of …

Preeclampsia is a serious medical disorder that affects 5% to 7% of pregnant women
worldwide, resulting in more than 70 000 maternal deaths and 500 000 fetal deaths per year …

Objectives Preeclampsia is associated with hypertension in later life, but the underlying
pathophysiological mechanisms remain uncertain. We aimed to explore whether the …

Preeclampsia (PE) is involved in a group of obstetrical conditions closely related by the
presence of placental dysfunction (PD), which also includes intrauterine growth restriction …

Background and objective: Angiogenic factors such as soluble fms-like tyrosine kinase 1
(sFlt-1) and placental growth factor (PlGF) play a key role in the pathogenesis of …